Drug Trial Radar · NCT07612150
A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Apr 30, 2028
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Merry Life Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as compared to participants receiving placebo.
Conditions
- Alzheimer Disease
Interventions
TML-6Drug
TML-6 tablets for oral administration.
PlaceboOther
TML-6 matching placebo tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Clinical Dementia Rating -Sum of Boxes (CDR-SB) Score at Week 52Time frame: Baseline and at Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.